Vijay Chechani
Pulmonary Disease · Roswell, NMNPI 1912960618
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 125 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 29.8% of the total. Reporting peaked in 2021 at $651 and has fallen 75.9% since, to $157 in 2025.
Across 125 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$669
- GSK$460
- Mylan Specialty L.p.$381
- Boehringer Ingelheim$275
- Jazz Pharmaceuticals Inc.$72
- Philips North America LLC$72
- plus $316 from 10 others
What the payments were for
- Food & beverage$2,15496%
- Education$924%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $669 |
| GSK | 30 | $460 |
| Mylan Specialty L.p. | 24 | $381 |
| Boehringer Ingelheim | 13 | $275 |
| Jazz Pharmaceuticals Inc. | 4 | $72 |
| Philips North America LLC | 3 | $72 |
| Inspire Medical Systems, Inc. | 2 | $64 |
| Pulmonx Corporation | 2 | $62 |
| Harmony Biosciences LLC | 1 | $45 |
| Actelion Pharmaceuticals US, Inc. | 2 | $32 |
| United Therapeutics Corporation | 1 | $24 |
| Gilead | 1 | $21 |
| Novartis | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Merck | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $14 |
How this compares
$2,246 in reported general payments places this provider in the 75th percentile of 56 pulmonary disease providers in New Mexico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 118 | $85,636 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $25,588 |
| Spiriva HandihalerTiotropium Bromide | 25 | $14,927 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $12,445 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $12,368 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $9,421 |
| Spiriva RespimatTiotropium Bromide | 13 | $8,612 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 46 | $7,035 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $4,532 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,940 |
| Fluticasone Propionate | 25 | $982 |
| Roflumilast | 14 | $839 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 27 | $749 |
| Ventolin HfaAlbuterol Sulfate | 12 | $657 |
| Theophylline ErTheophylline Anhydrous | 14 | $585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $460 | $125,178206 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $275 | $21,05725 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $669 | $16,30823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 56 pulmonary disease providers in New Mexico.
Other pulmonary disease in Roswell
- Stanislav BelyaevRoswell$895
- Lana Melendres GrovesAlbuquerque$1.1M
- Luke GabeSanta Fe$47K
- Michelle HarkinsAlbuquerque$24K
- Viral GandhiAlbuquerque$14K
- Gonzalo DiazAlamogordo$14K
- Arjan FloraAlbuquerque$10K
- Akshay SoodAlbuquerque$9K
- Alan OrellanaLas Cruces$5K
- Sivakumar NagarajuAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.